Background: Obesity is characterized by chronic low-grade systemic inflammation which can contribute to metabolic dysfunction. Diet is a modifiable factor that can help reduce this inflammation. Nuts such as almonds are rich in unsaturated fats, and antioxidant and anti-inflammatory micronutrients, which may work synergistically to attenuate obesity-related inflammation. Objective: To investigate whether daily almond consumption improves systemic inflammatory and immune markers in adults with obesity. Methods: In this randomized controlled parallel-arm trial, 69 adults (age: 30-45 years) with obesity (BMI: 30-45 kg/m2) were assigned to consume either 58 g/day of almonds (n = 30) or an isocaloric ultra-processed snack (cookie; n = 30) for six weeks. Fasting serum pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ), anti-inflammatory IL-10, innate immune cell counts, body weight, glucose, insulin, and lipid profile were measured at baseline and week six. Dietary intake, food compliance, palatability, acceptance, and appetite ratings were also assessed. Statistical analyses for primary outcomes included mixed model analyses and baseline-adjusted linear models. Results: Food compliance was high for both groups with greater acceptance for almonds. Almond consumption significantly decreased serum IL-6, TNF-α, and IFN-γ and increased IL-10 over 6 weeks compared with the cookie group (P < 0.05). No significant group differences were observed for innate immune cell counts, body weight, blood pressure, or serum fasting glucose, insulin, total cholesterol (C), LDL-C, and triglycerides over six weeks. Almond intake also increased monounsaturated fat, fiber, alpha-tocopherol, magnesium, zinc, manganese, and improved HEI, MED, and DASH dietary pattern scores (P<0.05). Conclusion: Daily almond consumption for six weeks improved inflammatory cytokine profiles and diet quality in adults with obesity, without changes in body weight under free-living conditions. These findings support almonds as part of healthy dietary patterns to help attenuate obesity-related inflammation.

JD received funding from the Almond Board of California for this study. VVP is Co-Investigator on the grant. Other authors have no disclosures.

NCT05530499

This study was funded by the Almond Board of California. The funding source had no role in the study design; collection, analysis, and interpretation of data; or writing and submission of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of University of Missouri-Columbia gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors